title: [Molecular target drugs of a malignant lymphoma and lymphoid leukemia].
authors.affiliation: Department of Hematology, Kitasato University School of Medicine.
authors.forename: Hirotoshi
authors.initials: H
authors.lastname: Kamata
authors.forename: Hirokazu
authors.initials: H
authors.lastname: Kimura
authors.forename: Masaaki
authors.initials: M
authors.lastname: Higashihara
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D056572:Histone Deacetylase Inhibitors / Q000627:therapeutic use; D006801:Humans; D000080045:Inotuzumab Ozogamicin; D007945:Leukemia, Lymphoid / Q000188:drug therapy*; D008223:Lymphoma / Q000188:drug therapy*; D058990:Molecular Targeted Therapy / Q000379:methods*; D061988:Proteasome Inhibitors / Q000627:therapeutic use; D011720:Pyrazoles; D011743:Pyrimidines; D054398:Receptors, CCR4 / Q000276:immunology; D000069283:Rituximab; D015398:Signal Transduction; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors
chemical_list: C108123:4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; C515354:CCR4 protein, human; D056572:Histone Deacetylase Inhibitors; D061988:Proteasome Inhibitors; D011720:Pyrazoles; D011743:Pyrimidines; D054398:Receptors, CCR4; C448700:epratuzumab; D000069283:Rituximab; C422802:ibritumomab tiuxetan; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D000080045:Inotuzumab Ozogamicin